D.K. received honoraria from AbbVie, AstraZeneca, Bristol Myers Squibb, Eisai, Chugai, Genmab, Gilead Sciences, Janssen, Sanofi, Asahi KASEI Pharma, Meiji Seika Pharma, Nippon Shinyaku, Ono, Otsuka Pharma, Pfizer, SymBio, and Takeda. K.Y. received honoraria from AbbVie and Nippon Shinyaku. S.T. received honoraria from AbbVie, Amgen, Daiichi-Sankyo, GlaxoSmithKline, Janssen, Asahi KASEI Pharma, Otsuka Pharma, Novartis, Pfizer, MSD, Astellas Pharma, Kyowa Kirin, Chugai, Nippon Shinyaku, Sumitomo Pharma, and Takeda. H.Y. received honoraria from Chugai, Novartis, Janssen, Takeda, AstraZeneca, Otsuka, Astellas, CSL Behring, JCR Pharma, MSD, Sumitomo Pharma, and Asahi KASEI Pharma. N.U. received grants from Chugai, Fuji Pharma, Sumitomo Pharma, Nippon Boehringer Ingelheim, and JCR Pharma; and honoraria from Chugai, Novartis, AbbVie, Kyowa Kirin, Takeda, MSD, AstraZeneca, Nippon Shinyaku, Daiichi Sankyo, CSL Behring, SymBio, Otsuka, Astellas, and Asahi KASEI Pharma. T.W. received honoraria from Chugai, Novartis, AbbVie, Alexionpharma, Amgen, Bristol Myers Squibb, Eisai, GlaxoSmithKline, Janssen, Meiji Seika Pharma, Mundi Pharma, Nihonkayaku, Ono, Pfizer, Sanofi, Kyowa Kirin, Takeda, AstraZeneca, Daiichi Sankyo, SymBio, Otsuka, Astellas, and Asahi KASEI Pharma. G.Y. received honoraria from AstraZeneca, Chugai, Genmab, Janssen, Meiji Seika Pharma, Mundipharma, Nihonkayaku, Novartis, Bristol Myers Squibb, Ono, Pfizer, Daiichi-Sankyo, Eisai, Sanofi, and Takeda. The remaining authors declare no competing financial interests.

All procedures performed in studies involving human participants were in accordance with the ethical standards of the insti- tutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all patients for being included in the study. The study was approved by the Institutional Review Board of Toranomon Hospital (1710-H).